Abstract 1559P
Background
Advancement of comprehensive genomic profiling (CGP) technology enables genomic medicine to emerge as a promising cancer treatment selection approach. As clinical implementation expands, concerns arise regarding equity of access and clinical utility. This study investigated the influence of ethnicity, socioeconomic status, and other factors on access to genomic testing at a trials unit in the UK. The clinical impact was also studied.
Methods
A retrospective review of patients referred for CGP between 2015 to 2024 was conducted. The impact of access by age, cancer types, ethnicity, and socioeconomic status defined by Index of Multiple Deprivation (IMD,1 - most deprived; 10 - least deprived) was assessed by comparing against population data from the UK Office for National Statistics. Clinical utility metrics including matching rates to targeted therapies, frequency of genomic aberrations, sequencing success rate, turnaround time were assessed based on medical records.
Results
Data from 406 patients was compared against the catchment area population. Patients from more deprived socioeconomic backgrounds were less likely to partake in CGP (p < 0.001). Black and mixed ethnic background were under-represented in the analysis population (p < 0.001). Clinical utility aligned with larger studies but only 31 (8.2%) patients were started on a matched targeted therapy. Table: 1559P
Summary of demographic characteristics
Age [years, median (range)] | 59 (24-85) |
External referral, n (%) | 120 (29.6%) |
Female, n (%) | 219 (53.9%) |
Ethnicity, n (%) | |
White | 236 (58.1%) |
Non-white | 73 (18.0%) |
Not recorded | 97 (23.9%) |
Socioeconomic status (IMD), n (%) | |
1-2 | 51 (12.7%) |
3-4 | 98 (24.4%) |
5-6 | 98 (24.4%) |
7-8 | 82 (20.4%) |
9-10 | 72 (18.0%) |
No results | 5 |
Cancer types, n (%) | |
Breast | 37 (9.1%) |
Endocrine | 9 (2.2%) |
Gynaecological | 66 (16.3%) |
Head and Neck | 7 (1.7%) |
Hepatobiliary and Pancreatic | 58 (14.3%) |
Upper GI | 21 (5.2%) |
Lower GI | 132 (32.5%) |
Skin | 4 (1.0%) |
Thoracic | 34 (8.4%) |
Urological | 33 (8.1%) |
Unknown Primary | 5 (1.2%) |
Median prior therapy lines, n | 3 |
Conclusions
Matching rate to targeted therapy or clinical trials remained low. The most common barriers were the lack of actionable mutation, unavailability of trials, and poor performance status. We also identified disparities of access to molecular testing associated with socioeconomic status and ethnicity. Current patient recruitment primarily relies on elective referrals from treating clinicians which could be a factor contributing to the observed disparity. Future efforts should focus on establishing a centralised, automated referral pathway.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Guy's and St Thomas' NHS Foundation Trust.
Funding
Has not received any funding.
Disclosure
J. Spicer: Financial Interests, Institutional, Advisory Board, Compensation to my employer for time providing advice: AstraZeneca, BMS, GSK, RS Oncology; Financial Interests, Personal, Stocks/Shares, Co-founder: Epsilogen; Financial Interests, Personal, Stocks/Shares: Avacta; Financial Interests, Institutional, Local PI, Reimbursement for treatment of patients in trial: Achilles, Roche, Trizell, BergenBio, MSD, Gilead, Iovance; Financial Interests, Institutional, Coordinating PI, Reimbursement for treatment of patients in trial: Starpharma, BMS, IO Biotech, RS Oncology; Non-Financial Interests, Leadership Role, National strategy board: Experimental Cancer Medicine Centres; Non-Financial Interests, Member of Board of Directors, Steering Committee: British Thoracic Oncology Group; Non-Financial Interests, Advisory Role, Advice on licensing decisions for MHRA: CHM Expert Advisory Group on Oncology & Haematology; Non-Financial Interests, Advisory Role, Advice on regulatory approvals: CHM Cancer Vaccines Expert Working Group. D. Sarker: Financial Interests, Personal, Advisory Board: Eisai, Ipsen, Bayer, Surface Oncology, AAA, AbbVie, Boehringer Ingelheim, AstraZeneca, Incyte; Financial Interests, Personal, Invited Speaker: MSD, Bayer, AstraZeneca, Eisai, Servier, Incyte; Financial Interests, Personal, Other, Travel and conference fees: Ipsen; Financial Interests, Personal, Other, Travel and Conference Fees: MiNA Therapeutics; Financial Interests, Institutional, Coordinating PI: UCB, MiNA Therapeutics; Financial Interests, Institutional, Local PI: Eisai, Medivir AB, MSD, Bayer, RedX, GSK, Starpharma, Adaptimmune, Blueprint, H3, Regeneron, Taiho, AstraZeneca, Ipsen; Financial Interests, Institutional, Funding: Roche, Inspirata; Non-Financial Interests, Advisory Role: Medivir, UCB, MiNA Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
1584P - Association of travel burden (TB) with colorectal cancer (CRC) outcomes in resource-limited settings (RLS)
Presenter: Saquib Banday
Session: Poster session 10
1585P - Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)
Presenter: Giovanni Maria Iannantuono
Session: Poster session 10
1586P - Current status of breast cancer: A comparative analysis between developed and developing countries
Presenter: Ana Isabel Martin Quesada
Session: Poster session 10
1587P - As seen through Hollywood’s lens: Cancer in movies, 2010-2020
Presenter: David Benjamin
Session: Poster session 10
1588P - Interventions to improve Herpes Zoster (HZ) vaccination rate among cancer outpatients receiving systemic treatments: A single-center real-world experience
Presenter: Sara Di Bella
Session: Poster session 10
1589P - Ramping up phase I trial recruitment: Defining potential barriers and disparities
Presenter: Burak Aktas
Session: Poster session 10
1590P - Prevalence and impact on survival of presentation to the emergency room of cancer patients: A retrospective study on real-life data
Presenter: Sonia Priou
Session: Poster session 10
1591P - Development and economic trends in new anticancer therapies licensed in the UK from 2020 to 2024
Presenter: Geetin Majhail
Session: Poster session 10
1592P - Awareness and interest of oncology professionals in sex and gender differences in cancer risk and outcome: Analysis of an ESMO Gender Medicine Task Force survey
Presenter: Berna C. Özdemir
Session: Poster session 10
1593P - Factors associated with multiple general practitioner consultations before cancer diagnosis in adolescents and young adults: A cohort study in Australia
Presenter: Jeremy Lewin
Session: Poster session 10